Abstract Details

Title Patient Characteristics and Real-world Use of Botulinum Toxins for Treatment of Chronic Sialorrhea

Topic Movement Disorders

Presentation(s) P4 - Poster Session 4 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-017

Objective We aimed to describe the demographics, clinical characteristics, and treatment patterns among patients with evidence of chronic sialorrhea.

Background Patients with neurological impairment may experience chronic sialorrhea, characterized by excessive drooling, which negatively impacts health and quality of life.

Design/Methods Patients aged ≥2 years with evidence of chronic sialorrhea were identified between 7/1/2007 and 5/21/2022 in Optum’s de-identified Clinformatics® Data Mart Database. Patients were required to have an incident diagnosis of disturbances of salivary secretion (ICD-9-CM: 527.7; ICD-10-CM: K11.7) and evidence of sialorrhea treatment (anticholinergics, botulinum toxins, or surgical excision) within the 30 days on or after diagnosis. We describe patient demographics, comorbidities, and treatment patterns prior to and after diagnosis. No statistical comparisons were conducted.

Results The final study population included 4,073 chronic sialorrhea patients. The majority of patients were 65+ years old (54%), male (55%), and non-Hispanic white (67%). The most common comorbidities at baseline were Parkinson’s disease (17%) and stroke (11%), reflecting common etiologies for sialorrhea. Anxiety (34%), depression (33%), and dysphagia (54%) were common following diagnosis. First-line oral anticholinergic therapy was more common than botulinum toxin use (69% vs. 34%) after diagnosis of sialorrhea. Less than 1% of patients had surgical excision. The median time until any treatment following diagnosis was 3 days [IQR: 0.5, 16]. Concurrent use of anticholinergic and botulinum toxin therapy was relatively infrequent (6%).

Conclusions This claims-based study provides insight into the characteristics of insured patients with chronic sialorrhea treated with anticholinergics, toxins, or surgical excision. Patients are commonly non-Hispanic White male patients ≥65 years of age. Off-label use of oral anticholinergics was more common than FDA-approved botulinum toxins therapy following diagnosis. The prevalence of comorbidities post-diagnosis suggests that there is a high burden of disease associated with sialorrhea.

Authors/Disclosures
Michael Hast PRESENTER	Michael Hast has received personal compensation for serving as an employee of Merz Therapeutics.
Amanda Kong (Aetion)	Amanda Kong has received personal compensation for serving as an employee of Aetion. Amanda Kong has stock in Aetion.
Jenna Abdelhadi (Aetion)	No disclosure on file
Andrew Szendrey (Aetion)	No disclosure on file
Rohan Shah (Aetion)	No disclosure on file
Jordan Holmes	Jordan Holmes has received personal compensation for serving as an employee of Merz Therapeutics.

��ɫ��

��ɫ��